$EVOK
Evoke Pharma Inc

2020 Q3 Form 10-Q Financial Statement

#000156459020052754 Filed on November 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.875M $810.0K $920.0K
YoY Change 131.43% -10.0% 0.0%
% of Gross Profit
Research & Development $210.0K $822.4K $1.206M
YoY Change -74.47% 30.55% -13.19%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.080M $1.637M $2.124M
YoY Change 27.06% 7.68% -7.91%
Operating Profit -$2.080M -$1.637M -$2.124M
YoY Change 27.06% 7.49% -7.91%
Interest Expense $50.53K $8.597K $9.642K
YoY Change 487.74% 178.31% 232.14%
% of Operating Profit
Other Income/Expense, Net -$49.50K $8.597K $9.642K
YoY Change -675.72% 178.31% 232.25%
Pretax Income -$2.130M -$1.630M -$2.110M
YoY Change 30.67% 7.24% -8.26%
Income Tax
% Of Pretax Income
Net Earnings -$2.129M -$1.628M -$2.114M
YoY Change 30.78% 7.15% -8.21%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$81.45K -$67.55K -$90.71K
COMMON SHARES
Basic Shares Outstanding 23.26M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.280M $6.500M $7.440M
YoY Change -3.38% -1.07% 13.94%
Cash & Equivalents $6.281M $6.505M $7.440M
Short-Term Investments
Other Short-Term Assets $11.55K $11.55K $11.55K
YoY Change 0.0% -97.37% -87.17%
Inventory $86.15K
Prepaid Expenses $775.6K $109.7K
Receivables
Other Receivables
Total Short-Term Assets $6.710M $7.292M $7.561M
YoY Change -7.98% 4.02% 14.05%
LONG-TERM ASSETS
Property, Plant & Equipment $40.00K $40.00K $70.00K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $40.00K $35.40K $69.80K
YoY Change 13.0% 253.98%
TOTAL ASSETS
Total Short-Term Assets $6.710M $7.292M $7.561M
Total Long-Term Assets $40.00K $35.40K $69.80K
Total Assets $6.750M $7.327M $7.631M
YoY Change -7.88% 4.38% 15.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $770.0K $1.150M $410.0K
YoY Change -33.04% 82.54% -6.82%
Accrued Expenses $750.0K $1.000M $880.0K
YoY Change -25.0% 2.04% 7.32%
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.620M $2.154M $1.285M
YoY Change 207.31% 33.8% 1.18%
LONG-TERM LIABILITIES
Long-Term Debt $2.000M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $50.00K
YoY Change
Total Long-Term Liabilities $2.053M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.620M $2.154M $1.285M
Total Long-Term Liabilities $2.053M $0.00 $0.00
Total Liabilities $8.674M $2.150M $1.290M
YoY Change 303.46% 33.54% 1.57%
SHAREHOLDERS EQUITY
Retained Earnings -$96.62M -$84.31M
YoY Change 14.59%
Common Stock $94.69M $89.49M
YoY Change 5.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.923M $5.173M $6.346M
YoY Change
Total Liabilities & Shareholders Equity $6.751M $7.327M $7.630M
YoY Change -7.87% 4.38% 15.08%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$2.129M -$1.628M -$2.114M
YoY Change 30.78% 7.15% -8.21%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.810M -$1.050M -$1.630M
YoY Change 72.38% -8.7% -7.39%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 110.0K 120.0K 5.040M
YoY Change -8.33% -89.92% 74.39%
NET CHANGE
Cash From Operating Activities -1.810M -1.050M -1.630M
Cash From Investing Activities
Cash From Financing Activities 110.0K 120.0K 5.040M
Net Change In Cash -1.700M -930.0K 3.410M
YoY Change 82.8% -2425.0% 201.77%
FREE CASH FLOW
Cash From Operating Activities -$1.810M -$1.050M -$1.630M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Inventory Net
InventoryNet
86145
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2019Q4 us-gaap Assets Current
AssetsCurrent
6245539
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
138538
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2019Q4 us-gaap Assets
Assets
6395628
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1033383
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
843162
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
138538
CY2020Q3 evok Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
104168
CY2020Q3 evok Milestone Payable
MilestonePayable
5000000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2015083
CY2020Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2053005
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8597
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
22868
us-gaap Interest Expense
InterestExpense
53442
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-48546
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
98165
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
21250
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1790309
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
310162
CY2020Q3 us-gaap Liabilities
Liabilities
8674314
CY2019Q4 us-gaap Liabilities
Liabilities
2015083
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
2633
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2443
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
94691151
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
90108492
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96617199
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85730390
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-1923415
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
4380545
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6750899
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6395628
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26332122
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24431914
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26332122
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24431914
CY2019Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
822444
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6450979
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2774924
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
814218
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4387284
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2955371
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
1636662
us-gaap Operating Income Loss
OperatingIncomeLoss
-10838263
us-gaap Operating Income Loss
OperatingIncomeLoss
-5730295
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8597
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4896
CY2020Q3 us-gaap Interest Expense
InterestExpense
50528
us-gaap Net Income Loss
NetIncomeLoss
-5707427
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24128060
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25191359
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21623648
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
362955
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5535326
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5800201
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
616823
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1185798
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5319004
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6504802
CY2020Q3 evok Issuance Of Common Stock From Stock Option Exercise Value
IssuanceOfCommonStockFromStockOptionExerciseValue
2627
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
4025320
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
378959
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
636432
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1965266
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3075445
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
344841
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5039956
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2114096
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
6346146
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
331303
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
123813
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
5173197
us-gaap Share Based Compensation
ShareBasedCompensation
1151691
evok Milestone Expense
MilestoneExpense
5000000
evok Accrued Interest Expense
AccruedInterestExpense
53442
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-261552
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
345975
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-498379
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4918503
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4614403
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3309116
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5800201
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
119415
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2627
us-gaap Proceeds From Issuance Of Unsecured Debt
ProceedsFromIssuanceOfUnsecuredDebt
104168
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p>
evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6119660
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5835226
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6119660
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5835226
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
871682
evok Issuance Of Common Stock From Warrant Exercise Shares
IssuanceOfCommonStockFromWarrantExerciseShares
381625
evok Issuance Of Common Stock From Stock Option Exercise Shares
IssuanceOfCommonStockFromStockOptionExerciseShares
4237
CY2020Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
0.62

Files In Submission

Name View Source Status
0001564590-20-052754-index-headers.html Edgar Link pending
0001564590-20-052754-index.html Edgar Link pending
0001564590-20-052754.txt Edgar Link pending
0001564590-20-052754-xbrl.zip Edgar Link pending
evok-10q_20200930.htm Edgar Link pending
evok-20200930.xml Edgar Link completed
evok-20200930.xsd Edgar Link pending
evok-20200930_cal.xml Edgar Link unprocessable
evok-20200930_def.xml Edgar Link unprocessable
evok-20200930_lab.xml Edgar Link unprocessable
evok-20200930_pre.xml Edgar Link unprocessable
evok-ex101_123.htm Edgar Link pending
evok-ex311_8.htm Edgar Link pending
evok-ex312_7.htm Edgar Link pending
evok-ex321_6.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending